Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase I Trial of LVGN7409 as Single Agent in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy

NCT05152212 is registered in ClinicalTrials.gov with Lyvgen Biopharma Holdings Limited as lead sponsor.

NCT NCT05152212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05152212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase I Trial of LVGN7409 as Single Agent in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy
Lead sponsor
Lyvgen Biopharma Holdings Limited
Phase
Phase 1
Overall status
Completed
Start date
September 29, 2021
Completion date
December 19, 2023
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer